| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.10B | -10.3% |
| Gross profit | ¥0.05B | — |
| Operating income | ¥-0.01B | — |
| Net income | ¥-0.01B | -150.1% |
| Gross margin | 51.8% | Net margin -8.2% |
| Revenue Q/Q | -19.1% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.05B | 48.2% |
| R&D | ¥0.02B | 21.6% |
| SG&A | ¥0.03B | 30.1% |
| Tax & other | ¥-0.00B | -0.6% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
欧陆通 ・ 回盛生物 ・ 天阳科技 ・ 海晨股份 ・ 捷强装备 ・ 蒙泰高新 ・ 金春股份 ・ 维康药业 ・ 大叶股份 ・ 迦南智能 ・ 盛德鑫泰 ・ 万胜智能
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies